Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Want to cut your energy bills? Here’s how five experts are doing it 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
LA JOLLA, Calif., May 30, 2017 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences.
- Jefferies 2017 Global Healthcare Conference, New York, June 6, 2017 at 2:00 p.m. EDT (11:00 a.m. PDT), company presentation and overview
- JMP Securities Life Sciences Conference, New York, June 20, 2017 at 2:00 p.m. EDT (11:00 a.m. PDT), Small Molecule Oncology Drugs: Challenges and Opportunities panel participant
A live audio webcast and replay of the presentation at the Jefferies conference will be available in the Investors section of Kura Oncology's website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected]
